

Medinice S.A.
ul. Stefana Hankiewicz 2
02-103 Warsaw, Poland

7 October 2026

CURRENT REPORT NO. 42/2026
DATED 7 OCTOBER 2026

Subject: Execution of agreements for preclinical and histopathological studies of the AtriClamp medical device

Legal basis

Article 17(1) of MAR – inside information

Report content

The Management Board of Medinice S.A., with its registered office in Warsaw (**the “Company” or the “Issuer”**), hereby announces that on 7 October 2026, the Company entered into agreements with **Veranex France SAS (“Veranex”)** for the conduct of preclinical studies in accordance with Good Laboratory Practice (“GLP”) and histopathological studies of the **AtriClamp** medical device developed by the Issuer.

The purpose of the studies is to assess the safety and efficacy of AtriClamp in an animal model and to obtain the data and documentation necessary for the further development of the project.

The execution of these agreements marks a further milestone in the development of the AtriClamp project and **brings the project significantly closer to the next regulatory stage towards obtaining CE certification**. The studies are intended to generate the data required for the further preparation of the device's technical documentation and for the subsequent stages of the conformity assessment procedure under Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (**“MDR”**).

AtriClamp is a medical device intended for external closure of the left atrial appendage.

The Issuer will disclose the results of the studies and further material milestones in the project's development, including those relating to the conformity assessment process and obtaining CE certification, in accordance with applicable laws.